GlassScriptPhysician profile
Michal J Bartel
NPI 1902036783
$6,202.17
in general payments reported to CMS, 2019-2025
12 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $1,500 · 2021: $1,169 · 2022: $77.27 · 2023: $161 · 2024: $1,611 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,850 · Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,850.00 |
| Food and Beverage | $452.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $3,350.00 | 2021-2025 | |
| Redhill Biopharma INC. | $1,609.12 | 2020-2021 | |
| Boston Scientific Corporation | $490.51 | 2019-2024 | Exalt Model D, Resolution 360 Clip |
| Olympus America INC. | $255.88 | 2023-2025 | Visiglide, Evis Exera III Video System Center |
| Intercept Pharmaceuticals, INC. | $105.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.01 | 2021 | |
| Steris Corporation | $101.44 | 2024 | |
| Gilead Sciences, INC. | $77.54 | 2021-2022 | |
| Braintree Laboratories, INC. | $53.64 | 2021 | |
| Abbvie INC. | $23.34 | 2021 | |
| Covidien LP | $20.01 | 2019 | |
| Concordia Pharmaceuticals INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michal Bartel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.